Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C7R-Epstein-Barr virus-specific T cells
- Development stage
- Phase 1
- Lead developer
- Baylor College of Medicine
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
C7R-Epstein-Barr virus-specific T cells (C7R-EBVSTs) are an adoptive cellular immunotherapy designed to treat Epstein-Barr virus (EBV)-associated malignancies. These autologous or allogeneic T cells are selected for their natural specificity against EBV antigens, typically including Latent Membrane Protein 1 (LMP1), LMP2, and EBV Nuclear Antigen 1 (EBNA1). To enhance therapeutic efficacy and overcome the immunosuppressive tumor microenvironment, the cells are genetically modified to express a constitutively active interleukin-7 receptor (C7R). This modification provides a continuous survival and growth signal mimicking the action of the cytokine IL-7, which promotes T-cell expansion, metabolic fitness, and long-term persistence without the need for exogenous cytokine support. Developed primarily at the Baylor College of Medicine, this therapy is currently being evaluated in clinical trials for patients with relapsed or refractory EBV-positive lymphomas, such as Hodgkin and Non-Hodgkin lymphoma.
- Other names
- C7R-modified EBV-specific T cellsC-7R-modified EBV-specific T cellsC 7R-modified EBV-specific T cellsConstitutively active IL-7 receptor-modified EBV-specific T cells
02
Targets
LMP2A (Latent membrane protein 2A)IL7R (Interleukin-7 Receptor)LMP1 (Epstein-Barr virus latent membrane protein 1)
Beyond the preview
Go deeper on C7R-Epstein-Barr virus-specific T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C7R-Epstein-Barr virus-specific T cells.